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Abstract: Alzheimer’s disease(AD) is associated with a variety of pathophysiological features, including amyloid 
plaques, inflammation, immunological changes, cell death and regeneration processes, altered neurotransmission, and age-
related changes. Retinoic acid receptors (RARs) and retinoids are relevant to all of these. Here we review the pathology, 
pharmacology, and biochemistry of AD in relation to RARs and retinoids, and we suggest that retinoids are candidate 
drugs for treatment of AD. 
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TOWARDS RETINOID THERAPY FOR ALZHEI-
MER’S DISEASE 
  The management of Alzheimer’s disease (AD) remains a 
challenge, even as our knowledge and understanding of AD 
continue to grow at an unprecedented rate [1-3]. Research 
that bridges the gap between basic science and clinical appli-
cation is extremely important for the development of new 
therapeutics. AD is a neurodegenerative disease, and has 
many pathological, biochemical and immunological features 
in common with Parkinson’s disease (PD), amyotrophic lat-
eral sclerosis (ALS), multiple sclerosis (MS) and spinal code 
injury (SCI). This paper deals mainly with AD in relation to 
retinoic acid receptors (RARs: RAR,  and ) and their 
ligands (retinoids), such as the endogenous RAR ligand all-
trans-retinoic acid (RA), taking into account knowledge 
about PD, ALS and other neurodegenerative diseases. It is 
important to note that factors leading to the onset of these 
diseases are still poorly understood, and so there is a great 
deal of scope for novel therapeutic approaches. Recent find-
ings indicate that the window of opportunity for enhancing 
or normalizing the growth of neuronal cells and promoting 
recovery from neurodegenerative diseases may be larger than 
previously thought.  
  AD is associated with a variety of pathophysiological 
features, including amyloid plaques, inflammation, immu-
nological changes, cell death and regeneration processes, 
altered neurotransmission, and age-related changes. Here, we 
will review how retinoids could be involved in all these fea-
tures of AD, together with the brief summary of their biol-
ogy, pharmacology, and medicinal chemistry. Fig. (1) shows 
the overview of the various potential therapeutic targets by 
retinoids discussed in this paper. 
MEDICINAL CHEMISTRY OF RETINOIDS  
  Retinoids are analogues of retinoic acid, an active me-
tabolite of vitamin A, and are specific modulators of cell   
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proliferation, differentiation, and morphogenesis in verte-
brates. There are many excellent reviews of the medicinal 
chemistry of retinoids  [4-10]. The term retinoid is used for 
substances which may be defined as (1) vitamin A related 
compounds (including vitamin A (retinol) and its biological 
precursor carotenoids, (2) RA (vitamin A metabolite), which 
activates RAR, , and , and synthetic analogs which bind 
with RARs with high affinity in an agonistic (similar bio-
logical activities to RA) or antagonistic manner, (3) com-
pounds which activate RXR,  and , which are nuclear 
receptors different from RARs, (4) compounds which mod-
ify the activities of RA by influencing metabolism, biosyn-
thesis or other pathways acting on co-factors, without bind-
ing to RARs or RXRs. We prefer to use the term retinoid in a 
strict sense, that is, compounds in category (2). It should be 
noted that the activity of vitamin A (retinol) is essentially 
due to RA generated by metabolism in vivo, except for the 
participation in vision via rhodopsin  [11-13]. Normally, a 
low level of RA is present (~10
–9~10 M), although a much 
larger amount (~10
-6 M) of vitamin A (retinol) is found in 
serum. The endogenous active retinoid is RA, which binds to 
and activates RAR, , and . Isomeric 13-cis-retinoic acid 
may also be an endogenous retinoid, but is less abundant 
than RA. 9-cis-Retinoic acid is synthesized from, or in equi-
librium with, RA, and it binds to and activates RAR, , and 
, and in addition RXR , , and . Many synthetic analogs 
with a variety of structures have been prepared, and show 
different receptor selectivities and elicit different pharmacol-
ogical effects from RA, including different adverse effects. 
Some act as antagonists which inhibit the activity of RA. 
BIOLOGICAL AND PHARMACOLOGICAL ACTIVI-
TIES OF RETINOIDS  
  The biological importance of RARs has been thoroughly 
documented elsewhere [14]. A number of genes are regu-
lated directly through the RAR or RXR- response elements 
through retinoic acid or retinoids binding to RAR of the 
RAR/RXR heterodimers, or indirectly, plausibly through the 
participation of the directly-regulated genes [15]. The bio-
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mostly covered in the above reviews [4-10]. An important 
practical clinical application of retinoids is in the treatment 
of acute promyelocytic leukemia (APL): treatment with RA 
results in complete remission in 90-95% of patients [16]. A 
synthetic retinoid, tamibarotene, works even on relapsed 
APL, which cannot be treated with RA [17]. Long-term 
maintenance treatments of APL patients using RA and tami-
barotene are in progress. More recently a review of retinoids 
for cancer and metabolic disease was published  [18]. Reti-
noids also inhibit angiogenesis [19]. Dermatological dis-
eases, in particular psoriasis, are treated with RA, etretinate, 
and tamibarotene [20, 21]. Psoriasis is now regarded as an 
autoimmune disease [22]. Furthermore, retinoids is effective 
in the treatment of collagen-induced rheumatoid arthritis and 
other autoimmune models [23-25]. They are also useful to 
prevent atherosclerosis and restenosis of vascular vessels 
[26, 27]. Retinoids suppress the differentiation of preadipo-
cytes to adipocytes [28], and promote alveolar regeneration 
in mammalian lungs [29]. Other observations suggest several 
clinical potential applications such as the treatment of dia-
betic retinopathy [30] and cataract [31]. Animal experiments 
using non-obese diabetic (NOD) mice suggested that reti-
noids may be effective to suppress type I diabetes and 
Schoegren’s syndrome [32]. Crohn’s disease is expected to 
be another treatment target [33, 34]. 
  Retinoids appear to normalize many pathological states, 
and the clinical side effects presently reported are mostly not 
serious except for retinoic acid syndrome, which seems spe-
cific to APL pathogenesis. Teteratogenicity remains an issue 
during the organ formation period in pregnancy: absolute 
contraception is required until complete clearance. Genotox-
icity has not been observed. Skin irritation often becomes a 
limitation in prolonged use for some retinoids; this may be 
caused by activation of the RAR [35-38].  
ALZHEIMER’S PATHOPHYSIOLOGY 
  Current status of AD research are well summarized in a 
number of books, reviews, journals including this journal, 
and elsewhere such as web site reports [1-3, 39]. The major 
pathophysiology of AD is cerebral atrophy and neuronal 
loss, neuritic plaques and neurofibrillary tangles. Other im-
portant questions are being discussed such as “are inflamma-
tory mechanisms actually causing damage in AD ?” [40] or 
“immune cells may fend off Alzheimer desease” [41]. Cell 
therapies of degenerated neural cells and tissues are of cur-
 
 
 
 
 
 
 
 
Fig. (1). Retinoid Dramatis Personae (Characters Involved in Retinoid Therapy). 
Neuron, dameged neuron, astrocyte (AS), microglia (MG), blood brain barrier (BBB), and other cellular members participate in the pathol-
ogy of Alzheimer's disease. Retinol bound to retinol-binding protein (RBP) and TTR is transported from blood into brain. Retinol uptaked by 
brain cells is oxidised into retinal, then converterd into retinoic acid (RA). Cellular RA level is also regulated by cellular retinoic acid-
binding proteins (CRABPs). By increase of -secretase activity through ADAM10 induction and by other pathaways, retinoids decrease 
amyloid- (A) deposition from APP.  
Inflammatory response triggered by amyloid- and other causes such as xenobiotics or chemicals is drived by inflammatory or proinflamma-
tory cytokines and chemokines (IL-1b, IL-6, TNFa, MCP1 and others). Their production is suppressed by retinoids through RARs expressed 
in astrocyte and microglia. Cell death may be inhibited by the decrease of A and suppression of inflammation. In regeneration from neural 
stem cells (NSC), retinoids have critical roles for their differentiation. Neurotransmission by Ach, DA and other molecules are affected by 
ChAT, dopamine D2 receptor (D2R), TrkB and t-PA which are transcriptionally regulated directly or indirectly by retinoid, influencing 
memory and learning. In addition, autoimmune pathways are regulated by T cells (Fig. 2 vide infra). In the scheme, + and - mean up-
regulation and down-regulation of the events or activities, by retinoids, respectively. 304    Current Alzheimer Research, 2009, Vol. 6, No. 3  Shudo et al. 
rent interests, but relating to that, regeneration by retinoids 
looks actual and now well-understood [42, 43]. Age-related 
decline of cognition which is a serious feature of AD, could 
also be a target phenomenon of a retinoid [44, 45]. Several 
evidence for the relationships between the late onset Alz-
heimer’s disease and retinoid defective signaling are shown 
[46, 47]. Now AD and other neurodegenerative diseases may 
be likely the therapeutic targets of retinoid. 
AMYLOID- HYPOTHESIS 
  AD is characterized by progressive memory deficits, 
cognitive impairment and personality changes due to neu-
ronal cell death in the hippocampus and frontal cortex. The 
histopathological hallmark of AD is senile plaques, which 
consist of insoluble amyloid-. Activated microglia and as-
trocytes (either proinflammatory or anti-inflammatory) sur-
round the amyloid plaques, and appear to be associated with 
the lesions. Reduction of amyloid- could be accomplished 
by inhibiting its production or aggregation, or promoting its 
degradation and removal, so active or passive immunization 
may have therapeutic potential. It has been shown that amy-
loid- specific antibodies can clear amyloid assemblies and 
amyloid- deposits in amyloid precursor protein (APP)-
transgenic mice. Amyloid--specific antibodies have been 
extensively studied as a mediator of amyloid clearance [48]. 
  APP is processed and fragmented by -secretase and -
secretase to generate amyloid-. However, the nonamyloi-
dogenic pathway of processing precursor proteins involves 
cleavage within the amyloid- peptide sequence. The identi-
fication of a member of the disintegrin and metalloprotease 
family (ADAM10) as an -secretase, whose expression can 
be regulated by retinoic acid, represents another therapeutic 
opportunity. Endogenous ADAM10 mRNA levels and the 
ADAM10 promoter activities were increased on RA treat-
ment in neuroblastoma cells: thus, retinoic acid works as an 
activator of the -secretase [49-51].  
  Dietary deficiency of vitamin A disrupts the retinoid sig-
naling pathway in adult rats, leading to deposition of amy-
loid- in the cerebral blood vessels via down-regulation of 
RAR- in the forebrain neurons and loss of choline acetyl-
transferase (ChAT) expression, and these changes were re-
versed by administration of retinoic acid [52, 53]. Pathologi-
cal samples from AD patients showed a similar RAR defi-
cit and deposition of amyloid- in the surviving neurons 
[52]. 
NEUROINFLAMMATION 
  For many years, the central nervous system was consid-
ered to be immunologically privileged, being neither suscep-
tible to, nor contributing to, inflammation. However, the 
Neuroinflammation Working Group suggested a relationship 
between inflammation and AD [40]. At least 600 reports 
indicate that the brain is by no means an immunologically 
isolated organ, and may have unique immunologic proper-
ties. Microglial-cell activation and migration, participation of 
astrocytes, and participation of various cytokines in AD have 
been confirmed. Microglia secrete proteolytic enzymes that 
degrade amyloid-, and play a neuroprotective role in AD. 
One of the chemokine receptors, CCR2 deficiency impairs 
microglial accumulation and accelerates the progression of 
AD-like disease in a model mouse, Tg2576 [41, 54]. More 
recently, Beers et al. showed CD4+ T cells, which can be 
recruited by MCP-1/CCR2 signaling, provides supportive 
neuroprotection by modulating the trophic/cytotoxic balance 
of glia in ALS mouse mode [55]. 
  Epidemiological studies indicate a reduced prevalence of 
AD among chronic users of nonsteroidal anti-inflamatory 
drugs, and clinical trials suggested a beneficial effect of 
some cycloxygenase (cox) inhibitors, although the effect is 
not related to the cox-inhibitory activity. Synthetic glucocor-
ticoids are potent ant-inflammatory agents that act by an-
tagonizing AP1 and NF-B promoter elements that regulate 
the transcription of inflammatory molecules. They are useful 
for the treatment of inflammation, but various biochemical, 
systemic and behavioral side effects and other contraindica-
tions exist for use in AD. In their review [40], Akiyama et al. 
concluded that “no more than nonsteroidal anti-inflammatory 
drugs (NSAIDs) cure arthritis will anti-inflammatory drugs 
cure AD. However, if AD neuroinflammation is approached 
with realistic expectations and rational drug design, AD pa-
tients should significantly benefit from anti-inflammatory 
treatment”. Suppression of inflammation in the brain is im-
portant in the treatment of many neurodegenerative diseases. 
  Other aspects of inflammation and immunology of neuro-
degenerative diseases have also recently been reviewed [56-
58]. Cytokines and chemokines, such as IL1, IL1, IL6, 
IL4, IL10, IL13 and MCP-1 are also important in AD. 
Though the action of IL6 generally depends on cellular and 
environmental conditions, unlike that of IL1, which pre-
dominantly has a proinflammatory effect, the cytokine may 
generally exert a damaging proinflammatory effect in the 
central nervous system, although it is present in normal brain 
tissues [59]. IL6 dysregulation is involved in many age-
related diseases, including autoimmune diseases. Chronic 
inflammation and astrocytosis are histopathological hall-
marks of AD patients, and astrocytes and microglia produce 
IL6 in response to amyloid- induced injury, thereby further 
promoting plaque formation. The induction of IL6 mRNA in 
the hippocampus and cortex of APPsw transgenic mice 
Tg2576 may be crucial in the early onset of AD [60]. The 
association of –174G/C and –572G/C mutations of IL6 pro-
moters with AD has been discussed, but remains contentious 
[61, 62]. 
  Since retinoids strongly suppress the production of IL6 
[63, 64], the suppression of IL6 by retinoids may be benefi-
cial for the treatment of AD. Retinoids also inhibit LPS- or 
amyloid--induced TNF- production, and expression of 
inducible NO synthase (iNOS) in activated microglia; these 
effects may be mediated via the inhibition of NF-B nuclear 
translocation. Retinoids inhibit many aspects of microglial 
activation [65, 66]. Thus, retinoids seem to have consider-
able potential from the standpoint of suppression of inflam-
mation in neurodegenerative diseases. 
AUTOIMMUNE FEATURES 
  Immune system alterations during aging are complex and 
pleiotropic. Generally, changes of the T cell component are 
age-dependent. It is always difficult to determine whether 
changes are associated with aging itself or a result (or a 
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brain have been relatively limited because of the supposed 
immune privilege of the brain, the role of immunology can-
not be neglected in AD (or PD), as well as in the representa-
tive autoimmune neurodegenerative disease, MS. It is, how-
ever, interesting that up-regulation of major histocompatibil-
ity complex (MHC) class I and II on glial and neural cells 
occurs in AD, in addition to production of inflammatory cy-
tokines and limited T cell infiltration [40, 67], and the gen-
eration of autoreactive antibodies and T cells against amy-
loid- [68] . Similar findings were reported in PD and ALS 
[69-72]. Thus, there is a possibility that an appropriate 
modulation of autoimmune response may prevent disease 
development. In other words, changes in the activity or 
population of T cells may influence the progression of AD, 
PD and other such diseases.  
  Recently, IL-17-producing helper T cell subset, Th17 is 
at the center of attention in autoimmune research [73, 74]. 
The importance of Th17 cells in central nervous system in-
flammation in MS patients and experimental autoimmune 
myasthenia gravis in C57BL/6 mice has been shown [75, 
76]. IL17 and IL22 receptors are expressed on blood-brain-
barrier (BBB) endothelial cells in MS lesions, and these cy-
tokines disrupt BBB tight junctions in vivo and in vitro. 
Thus, Th17 lymphocytes transmigrate efficiently across the 
BBB, killing human neurons and causing central nervous 
system inflammation through CD4+ lymphocyte recruitment. 
It was also shown that the BBB induces differentiation of 
migrating monocytes into Th17-polarizing dendritic cells 
[77]. The abundance of dendritic cells promotes secretion of 
IL12p70, TGF and IL6, as well as the proliferation and 
expansion of distinct populations of IFN-secreting Th1, and 
IL-17-secreting CD4+ Th17 lymphocytes. Such cells are 
closely associated with microvascular BBB endothelial cells 
within acute MS lesions. It has also been shown that im-
pairment of the function of tight junctions facilitates the in-
vasion of inflammatory cells prior to motor neuronal degen-
eration in ALS-causing SOD1 mutant mice [78]. Similar 
BBB disruption may be involved in the early onset of AD, as 
well as other neurodegenerative disorders. The suppression 
of Th17 or the restoration or maintenance of the function of 
tight junctions has a favorable effect, slowing the progres-
sion of autoimmune diseases. It is noteworthy that experi-
mental autoimmune encephalomyelitis (EAE) mice or rats, 
an animal model of MS, has been successfully treated with 
retinoid [79-81]. Psoriasis, which is an important clinical 
target of retinoid, is now regarded as an autoimmune disease 
[22]. 
T CELL DIFFERENTIATION 
  If T cells play a significant role in neurodegenerative 
diseases, their differentiation status must be important (Fig. 
2). For two decades, it has been known that the CD4+ cells 
among the naïve T cells can differentiate into two types of 
helper T cells, Th1 cells, which express the transcription 
factor T-bet (activated by IFN), and Th2 cells, which ex-
press the transcription factor GATA3 (activated by IL4). In 
this classical Th1/Th2 paradigm, which is revised by recent 
emergence of Th17, Th1 activation appears particularly im-
portant in tissue-specific autoimmunity such as EAE, and 
Th2 seems to be important in more systemic autoimmunity 
such as systemic lupas erythematosus (SLE) and allergic 
disease, though the key point is likely to be the balance be-
tween Th1 and Th2. It is noteworthy that the Th1 pathway is 
suppressed by RA (or retinoids), and the Th2 pathway is 
somewhat activated [82]. Retinoids are often beneficial for 
the treatment of autoimmune disease depending on the char-
acteristics of the retinoid and the Th1/Th2 ratio of the dis-
ease [83]. A striking recent finding is that CD4+ naïve T 
cells, independently of Th1- and Th2-cell development, can 
differentiate to another helper T cell subset, Th17, which 
produces IL17 and expresses transcription factor retinoid-
related orphan receptor t (RORt) [84]. Th17 cells are im-
plicated in the pathogenesis of various autoimmune condi-
tions, as mentioned in previous section, and supposed to be 
the major cause of rheumatoid arthritis, Crohn’s disease, 
psoriasis, MS and other diseases.  
  These effector T cells, Th1, Th2, and Th17 are sup-
pressed by another CD4+ T cell subset of reguratory Tcells, 
Treg [85, 86]. A specific marker for Treg is the Foxp3 [87, 
88]. The role of Treg cells in self-tolerance, autoimmune 
diseases and anti-tumor immunity has been actively studied 
in recent years. The decrease of Treg function may cause or 
progress breakdown of immune homeostasis. For example, 
the involvement of Treg has been demonstrated in MS [89], 
myasthenia gravis [90], and human T-lymphotropic virus 1 
(HTLV-I) associated neuroimmunological disease [91]. 
Therapies for activation or proliferation of Treg may be use-
ful for these autoimmune diseases. 
  This is also the case in the neurodegenerative diseases. 
Rosenkranz et al reported the involvement of Treg in AD 
and PD [92]. Analysis of Treg from AD and PD patients, as 
well as non-affected individuals, revealed that the frequency 
of Treg (CD4+ Foxp3+) increases with age and the increase 
is accompanied with intensified suppressive activity of Treg 
in patients. This may reflect a biological homeostatic re-
sponse to the disease. Rosenkranz et al speculated that 
changes in Treg might affect disease-related immune mecha-
nisms, since it has been hypothesized that neuroinflamma-
tion may be a response that is aimed at blocking disease de-
velopment. The important role of Treg in PD was experi-
mentally demonstrated in a MTPT (N-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine)-treated mouse model: Treg that 
highly expressed Foxp3 and IL10 was found to mediate neu-
roprotection through suppression of microglial activation 
[93].  
  In these respects, it is striking that CD4+ Foxp3+ T cell 
development from naïve CD4+ T cells is strongly induced by 
co-treatment with TGF and retinoid, including RA and syn-
thetic retinoids such as Am580, and is suppressed by the 
retinoid antagonist LE540 [94-102] (Fig. 1). It is claimed 
that Treg is induced at the expense of IL17-secreting T cells 
by retinoic acid via RAR [102]. However, it is not yet clear 
whether Th17 cells are convertible to Treg, and also whether 
or not Foxp3-positive cells induced by RA and retinoids are 
true Treg. Much remains unclear about the roles of the vari-
ous T cell subsets, but the importance of retinoids in T cell 
differentiation seems now clear. And, there is a proposal as 
to whether oral tolerance is all due to RA [103], where the 
author expects the use of Treg cells in the clinic and new 
RAR agonists other than RA with less side effects for in vivo 
uses.  306    Current Alzheimer Research, 2009, Vol. 6, No. 3  Shudo et al. 
INFECTION 
  Infection could be a cause for breakdown of immune 
system and trigger autoimmune diseases. There is a hypothe-
sis that AD is an autoimmune disease caused by an infection, 
but others have doubted a role of viral or other infection 
[104-106]. The role of infection with herpes simplex, spiro-
chetes, and chlamydophila in AD has recently been reviewed 
[67, 107-109]. A role of infection would be consistent with a 
recent report that a group of ALS patients showed an ex-
tremely high frequency of systemic mycoplasmal infections 
[110].  
  Various routes of infection, such as gut, nasal, skin and 
lung, involving viruses, bacteria, specific proteins and 
chemical substances have been discussed. The olfactory vec-
tor hypothesis is that xenobiotics, including viruses and tox-
ins, immunologically pull the trigger leading to neurodegen-
eration [106, 111]. This hypothesis is supported by the find-
ing that olfactory dysfunction is a risk factor for PD and AD 
[111-113]. The normal differentiation and regeneration of 
olfactory-related cells are also regulated by retinoic acid, and 
vitamin A therapy in animals with olfactory system damage 
can accelerate functional recovery through RARs and reti-
noid X receptors (RXRs): retinoic acid supports the integrity 
of the olfactory system throughout life [114, 115]. The main-
tenance of olfactory function by retinoid may be preventive 
for the disease. Pathogens may elicit an autoimmune re-
sponse without persistence of the initiating agent, environ-
mental factors and nutrition being critical determinants of the 
onset.  
REGENERATION OF NEURAL CELLS 
  A possible approach to neurodegeneration is neural stem 
cell therapy. It is now well established that cells in the cen-
tral nervous system can regenerate under certain conditions. 
Advances in techniques to isolate and manipulate neural 
stem cells offer new scope for functional recovery after cen-
tral nervous system injuries. 
  Patterning into forebrain, midbrain, hindbrain, and spinal 
cord involves a complex series of morphogenic movements. 
Further differentiation is also strictly regulated: for example, 
stem cells at the CA1 region of hippocampus differentiate 
into the neural cells of CA1. It is also important that regen-
eration stops at the appropriate point. In many cases of re-
generation and differentiation in neural injuries, retinoic acid 
is involved, or retinal dehydrogenases (RALDH) are pro-
duced. For example, inflammation reactions caused by spinal 
cord contusion in rats were followed by an increase of 
RALDH2 enzyme activity and local synthesis of RA [116-
118]. Intracellular translocation of RAR (and RXRs) into 
the nuclei of activated macrophages, surviving neurons and 
astrocytes near the lesion site has been reported [119]. The 
localization of retinoid receptors in Schwann cells correlated 
with inflammatory transduction pathways of IL1, IL6 and 
TNF [120]. 
 
 
 
 
 
 
 
 
Fig. (2). Multiple actions of retinoid inT cell differentiation.  
Naive CD4-positive T cells differntiate into effector T cells (Th1, Th2, Th17) and regulatory T cells (Treg) in peripheral lymphoid tissues. 
Th1 cells whose differentiation is dependent on IL-12 and suppressed by retinoids mediate cellular immunity and physiologocal (and patho-
logical) inflammation. Th2 cells mediate humoral immunity and allegy. Their differentiation is dependent on IL-4 and enhanced by retinods, 
but suppressed by coexistence of retinoids and TGF. IL-17-producing Th17 cells mediate pathological chronic inflammation or autoim-
mune inflammation. Th17 diffrentiation is induced by coexistence of IL-6 and TGF, and maintained by IL-23. By contrast, differentiation 
of Treg cells is induced by TGF alone and suppressed by IL-6. Treg cells suppress effector T cell activities and and thereby maintain im-
mune system homeostasis and self-tolerance. Retinoids strongly enhance TGF-induced Treg diffenentiation and suppress Th17 differentia-
tion even in the presence of IL-6. Towards Retinoid Therapy for Alzheimer’s Disease  Current Alzheimer Research, 2009, Vol. 6, No. 3    307 
  The activities of RA in in-vitro differentiation, as well as 
in the development of vertebrates, have been known for a 
long time. RA can induce the complete regeneration of or-
gans that cannot normally regenerate, such as mammalian 
lung and retina, by respecifying positional information [42, 
121]. Murine F9 teratocarcinoma stem cells have been 
widely used as a model for cellular differentiation and RA 
signaling during embryonic development [122]. Induction of 
neural differentiation by retinoid has been shown in several 
embryonal carcinoma cell lines [123-125]. Many studies on 
pattern formation have confirmed the importance of retinoids 
in spinal cord and brain development [126]. These findings 
prompted detailed analyses of RARs in brain [127], and ex-
tensive studies of RAR signaling pathways in neurological 
diseases [47]. The results suggest that RA or more generally 
retinoids are potential therapeutic agents for the treatment of 
neurodegenerative diseases, promoting tissue regeneration. 
Studies are advanced in the case of acute phase treatment of 
SCI. Mey analyzed the distribution and re-distribution of 
RARs after SCI [119]. Maden showed the importance of 
RARs in SCI, and found that RAR gene introduction and 
the coexistence of a RAR ligand (rather than RAR) caused 
neurite growth and improved the recovery of animals after 
trauma [126, 128, 129]. Takenaga recently observed similar 
therapeutic effect in physically injured rats treated with the 
synthetic retinoid tamibarotene [17] which is RAR and 
RAR specific (unpublished). Since the physical contusion 
is accompanied by inflammation and activation of microglia 
and macrophages, the therapeutic effect may not be simply 
explained, but at least re-generation and differentiation of 
neurite cells are promoted by retinoid in an adjuvant fashion.  
  Of course, other nuclear receptors (and their ligands) in 
addition to RARs participate, particularly RXRs, RORs, liver 
X receptor (LXR), orphan nuclear receptor NR4A2 (Nurr1) 
[130], and peroxisome proliferators-activated receptors 
(PPARs) [131]. The expression profile and functional role of 
nuclear receptors in such retinoid signaling have been pro-
filed in human SCI, ALS, AD and PD [132].  
NEUROTRANSMISSION 
  Particular hallmarks observed in AD are the changes of 
cholinergic neurotransmission, which cause the decrease of 
acetylcholine (ACh). It was reported that vitamin A deficient 
rats with cognitive deficits showed impaired scopolamine-
evoked release of ACh owing to blockade of the presynaptic 
acetylcholine autoreceptor. The impaired release of ACh is 
probably caused by lower production of ChAT, as well as 
neural cell death, mediated by RA and the gene promoter 
[133, 134]. 
  An increase of ChAT seems to be beneficial, and it has 
been suggested that the vascular ACh transporter is also 
regulated by RA [135]. Retinoid rescued scopolamine-
induced memory deficits in a passive avoidance paradigm 
[136]. This result could not be satisfactorily explained, but 
may support the participation of ACh and ChAT in the sco-
polamine-related memory deficit. In addition, retinoids also 
regulate the expression of tyrosine hydroxylase, dopamine 
hydroxylase and the dopamine D2 receptor. RA directly 
regulates D2 receptor expression via interaction with a RA-
response element (RARE) at the promoter [137]. Such mem-
ory acquisition may not be explained simply by the partici-
pation of neurotransmitters. 
LEARNING AND MEMORY 
  The physiological role of retinoids in hippocampal func-
tion of adult brain has been reviewed by Lane and Bailey 
[138]. The enzymes that synthesize RA and RALDH protein 
are restricted to the meninges surrounding the hippocampus 
in adult brain. The presence of cellular retinol binding pro-
tein 1 (CRBP1) and cellular retinoic acid binding protein 1 
(CRABP1) in the dendritic layers of the hippocampal forma-
tion and dentate gyrus has been demonstrated. RAR and 
RAR, rather than RAR-, are highly expressed in hippo-
campal CA1, CA2 and CA3 regions. RXRs are also ex-
pressed. These findings suggest that RA (and therefore reti-
noids) may play a central role in memory and spatial learn-
ing. Impaired long-term potentiation (LTP) and long-term 
depression (LTD) have been demonstrated in mice lacking 
RAR  alone, or RAR  and RXR  [139]. Loss of synaptic 
plasticity is observed in vitamin A deficient mice [44] or 
aged mice [140, 141]. The reductions of LTD and LTP are 
partially reversed by RA, although the precise involvement 
of specific genes in the regulation of synaptic plasticity has 
not been elucidated. 
 Etchamendy  et al. [140] demonstrated that pharmacol-
ogical activation of retinoid signaling by short-term RA ad-
ministration to aged mice restored their hippocampal retinoid 
target-gene hypoexpression, as well as their long-term de-
clarative memory (LTDM) and hippocampal LTP deficit. 
Further, hippocampal retinoid receptor RAR/RXR signal-
ing is critically implicated in the cellular mechanism sustain-
ing LTDM, as well as short-term working memory systems 
[45]. LTP-related genes, tyrosine kinase B (TrkB) and tissue 
plasminogen activator (t-PA), are reported to be the RAR-
target genes and induced in neurobalstoma cells by treatment 
of retinoic acid [142-144]. TrkB is the receptor for brain-
derived neurotrophic factor (BDNF), which is a key regula-
tor for protein synthesis-dependent LTP and long-term 
memory and whose maturation is dependent on t-PA-
mediated cleavage of proBDNF [145]. RAR / RXR knock-
out mice behaved similarly to the aged mice and it was 
shown that RAR and expression of neuromodulin (Gap43) 
gene, a plasticity related retinoid-target gene, are important. 
This paper also reviewed the literature on this subject. 
  Another interesting observation was the involvement of 
transthyretin (TTR), which was identified as a key protein by 
microarray analysis of genes associated with age-related 
memory deficits [146]. TTR is a serum and cerebrospinal 
fluid carrier of the thyroid hormone, thyroxine. TTR is also a 
carrier of retinol from liver storage to target tissues in 
association with retinol binding protein (RBP) [147]. TTR 
has been reported to be the major amyloid- binding protein 
in cerebrospinal fluid. Age-related memory deficits occurred 
in TTR-/- mice in the water maze work task, and surpris-
ingly, the deficits were improved by uptake of RA [146]. It 
has been shown that AD patients have lower levels of TTR 
[148]. TTR and possibly a similar serum protein, insulin-like 
growth factor I (IGF-I) regulate brain amyloid- levels [149, 
150]. Decreased levels of TTR may affect retinoid homeo-
stasis, which is required to regulate neurogenesis and differ-
entiation. 308    Current Alzheimer Research, 2009, Vol. 6, No. 3  Shudo et al. 
  The appearance of new neurons in the hippocampus and 
cortex during adulthood seems to be linked to memory and 
learning [151]. Interestingly, in AD patients, an increased 
number of newly generated cells was observed in the granule 
cell layer, as well as the CA1 region of Ammon’s horn, 
where extensive cell death occurs during the disease [152]. 
Retinoids may have important roles in such neurogenesis. 
CONCLUSION 
  Much research in AD is still aimed at elucidating basic 
pathomechanisms, although over seventy-five compounds 
are in clinical development for treatment of AD [39].  
  Retinoids are required for the maintenance of the im-
mune systems, and are very potent immunomodulators. They 
suppressively regulate various autoimmune disease states, 
and being different from simple immunosuppresants, work 
physiologically even when applied at high pharmacological 
concentrations.  
  Retinoids are essential in the regeneration of neural cells 
and other tissues. Development of retinoids that are highly 
selective for individual RARs may contribute to the treat-
ment of AD and other neurodegenerative diseases. Recently 
there came out a review emphasizing significant roles of 
retinoids for treatment of neurodegenerative diseases such as 
ALS, AD and schizophrenia [153]. We did not cover RXRs 
and RXR ligands here, though these may have a role in in-
creasing the selectivity of retinoids, and they seem to have 
important roles in mental activities such as sleep regulation, 
reward-related behaviors [154-158].  
  Retinoids were suggested long ago to have potential for 
the therapy of various proliferative diseases [159]. Some 
applications have been realized, and our task now is to ex-
tend the range of applications to neurodegenerative diseases, 
including AD.  
ABBREVIATIONS 
AD =  Alzheimer’s  disease 
PD =  Parkinson’s  disease 
ALS  =  Amyotrophic lateral sclerosis 
MS =  Multiple  sclerosis 
SCI =  Spinal  code  injury 
RARs  =  Retinoic acid receptors 
RA =  all-trans-retinoic acid 
APP  =  Amyloid precursor protein 
ChAT =  Choline  acetyltransferase 
Treg =  Regulatory  T  cells 
EAE  =  Experimental autoimmune encephalomyelitis 
RXRs  =  Retinoid X receptors 
RORs  =  Retinoid-related orphan receptors 
RALDH =  Retinal  dehydrogenase 
Ach =  Acetylcholine 
CRBP1  =  Cellular retinol binding protein 1 
CRABP1 =  Cellular retinoic acid binding protein 1 
TTR =  Transthyretin 
APL =  Acute  promyelocytic  leukemia 
NOTE ADDED IN PROOFS 
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